into those with mild cardiac dysfunction (LVEF < 0.50 > 0.40) and severe heart failure (LVEF < 0.20) and given graded sequential infusions of dobutamine and calcium gluconate. Those with severe cardiac dysfunction had marked impairment of the dobutamine dP/dt and stroke work index response, whereas these responses to calcium did not differ in the two groups. These data indicate that in the intact human heart (1)
of myocarditis, transplant rejection, and anthracycline cardiotoxicity, as well as in some metabolic studies. 9' 10 The recent introduction of iodinated radioligands with high specific activity and high affinity for /-adrenergic receptors, such as (-) ['25l ]iodocyanopindolol (ICYP),`1 has made possible the measurement of /3-adrenergic receptor density in milligram quantities of tissue. Such measurements are important because they would make available a spectrum of patients with varying degrees of myocardial dysfunction for receptor and other biochemical analyses. More important, such measurements would allow for direct assessment of the /3-adrenergic pathway in the intact human heart, as compared with examination of hearts that have been subjected to anesthesia, surgical procedures, and a variety of preoperative systemic influences.
We report our initial results of the assessment of the /3-adrenergic receptor pathway in the intact human heart with tissue removed by endomyocardial biopsy and measurement of the functional response to the l3-agonist dobutamine. The data indicate that ,8-receptors may be directly identified in endomyocardial biopsy tissue, that ,3-adrenergic receptor down-regulation occurs in hearts with mild to moderate dysfunction as well as in severely failing hearts, that in heart failure the degree of receptor down-regulation is related to the degree of cardiac dysfunction, and that /3-receptor down-regulation is associated with a specific blunting of the contractile response to /3-agonists.
Materials and methods
Patients. The study population consisted of 38 consecutive subjects who had undergone right ventricular biopsy (n = 38), cardiac catheterization (n = 38), and measurement of ejection fraction (n = 37) by either contrast (n = 18) or radionuclide (n = 19) techniques between March 1, 1983 , and March 1, 1985 , at either Stanford University Hospital or the University of Utah Medical Center. Five patients with normal ventricular function were evaluated in an investigation of the cardiotoxicity of an anthracycline antibiotic analog, 4' epidoxorubicin. These subjects all had low doses of 4' epidoxorubicin (<400 mg/M2) and none had a biopsy score of greater than 2.0 on the Billingham scale12 of anthracycline damage. Another subject was being treated with a cardiotoxicity-sparing dose schedule of doxorubicin (adriamycin) and had a grade 2.0 biopsy score with normal hemodynamics at rest and exercise at a total cumulative doxorubicin dose of 1050 mg/mi2. An additional subject with normal ventricular function was evaluated because of apparent familial cardiomyopathy in his offspring and was found to have normal hemodynamics at rest and exercise. Patients with biventricular dysfunction by hemodynamic measurements or by disease etiology included subjects with idiopathic (n = 26), anthracycline (n = 1), anthracycline plus other causes (n = 2), and diabetic cardiomyopathy (n = 1). Twenty-three subjects with ventricular dysfunction underwent left heart catheterization and coronary angiography, and with the exception of the one subject with diabetic cardiomyopathy, none had coronary artery narrowing of greater than 50%. This subject had three-vessel coronary disease, no history of myocardial infarction, and diffuse hypokinesis on ventriculography.
Patients were excluded from this study if they were older than 60 years, had heart failure secondary to ischemic heart disease by history, electrocardiography, or coronary arteriography, had significant lung disease, or had valvular heart disease exclusive of mild-to-moderate mitral or tricuspid regurgitation thought to be secondary to dilated cardiomyopathy.
Radionuclide ventriculography was performed as previously described.'3 When subjects underwent both contrast and radionuclide ventriculography, the contrast value was used. All subjects had radionuclide ventriculography within 1 week of catheterization. For analysis of data within the three treatment groups, contrast and radionuclide values were considered equal.
Subjects were divided into three groups based on left ventricular ejection fraction (LVEF). Group I consisted of subjects without ventricular dysfunction with an LVEF of 0.50 or greater. Group II included subjects with an LVEF of less than 0.50 but greater than 0.25. Group III comprised subjects with severe ventricular dysfunction and an LVEF under 0.25. Informed written consent was obtained from all patients, and this research was approved by the institutional review boards at both institutions.
Endomyocardial biopsy. Right ventricular endomyocardial biopsy specimens were obtained from all subjects. In six subjects in group I and two subjects in group II, studies were performed on an outpatient basis. The procedure of right ventricular endomyocardial biopsy has been described in detail elsewhere.' Briefly, a No. 9F sheath is inserted percutaneously into the right internal jugular vein under local anesthesia. A 50 cm right ventricular bioptome is then inserted through the sheath into the right ventricle and positioned against the intraventricular septum. In the current study, multiple specimens (two or three) were obtained for morphologic examination by both light and electron microscopy, and three to six specimens were obtained for /3-adrenergic receptor analysis.
After biopsy, right heart catheterization was performed, through the same sheath with either a No. 7F Cournand catheter or a balloon-tip catheter (Critikon Corp.), with a reduction sleeve on the sheath. Cardiac output was measured by the Fick method. Left heart catheterization, coronary angiography, and left ventricular ventriculography were performed by standard techniques.
Membrane preparation. The biopsy specimen was immediately placed in 10 ml of ice-cold 10 mM Tris, 1 mM EGTA buffer, pH 8.0, and grossly visible fibrous tissue was dissected free. The remaining sample was compiled as an aggregate, blotted dry, and weighed. Tissue weight ranged from 10.6 to 57.7 mg, with a mean + SD of 25.2 + 10.2 mg. The samples were placed in 40 ml of ice-cold Tris-EGTA buffer and homogenized in a Polytron (Brinkmann Instruments, Westbury, NY) by three consecutive 3 sec bursts at the maximum setting of 11.
One milliliter of ice-cold 2.5M KCl was then added to extract contractile proteins,' followed by stirring at 40 C for 15 min.
The suspension was then centrifuged at 50,000 g for 15 min and resuspended with a quick burst in the Polytron and recentrifuged and resuspended in the same manner. After a third centrifugation the preparation was suspended in the final assay buffer at a final concentration of 1 to 3 mg of original tissue to 1 ml of buffer and used for receptor binding assays.
For where X = radioligand concentration, was performed as previously described. 4 Specifically bound ICYP was derived by subtraction of the linear fit of the nonspecific binding curve from the total binding curve, as previously described. 4 Linear plots'5 were also performed but were used only for data inspection. In calculating the specific activity of ICYP, ICYP was assumed to undergo transformation into non-/3-receptor active breakdown products in direct relation to radioisotope decay. 16 In kinetic experiments, the dissociation rate constant (k2 The distribution of /8-adrenergic receptors, isoproterenol-stimulated adenylate cyclase activity, and various membrane markers in right ventricular endomyocardium, right ventricular free wall, and left ventricular free wall are also given in table 1. Although ,8-receptor density and 5' nucleotidase activity are comparable in right ventricular endomyocardium and free wall, adenylate cyclase activities appear to be lower in endomyocardium compared with right ventricular free wall. Left ventricular free wall had a slightly greater 8-receptor density than did right ventricular free wall or endomyocardium, but the small difference was not statistically significant. Relative to right ventricular tissue, left ventricular myocardium had statistically greater forskolin--and isoproterenolstimulated cyclase activities but similar 5' nucleotidase activity.
Radioligand binding. Figure 1 demonstrates that specifically bound ICYP is linear with respect to added protein between concentrations of 3 and 443 ug/ml. In figure 2 , specifically bound ICYP demonstrates stereospecificity for competition by the (-) isomer vs the (+) isomer of isoproterenol. The rank order of potency for various agonists given in figure 2 is: (-) isoproterenol > epinephrine = norepinephrine, which is the order of potency for a predominately ,/3-receptor population. Results similar to those shown in figures 1 and 2 were obtained in two other preparations.
Kinetic data from a representative experiment are given in figure 3 and reveal rather slow onset kinetics, with steady state achieved by 105 min. The offset kinetics are extremely slow, as shown in the left-hand panel of figure 3 . The KD determined from the kinetic cyclase activity and a lower ratio.
isoproterenol/fluoride Morphologic analysis. With the exception of three subjects with doxorubicin cardiomyopathy, biopsy specimens from all subjects in groups II and III demonstrated varying degrees of hypertrophy on light microscopy. Four subjects in group II and 13 subjects in group III had evidence for increased interstitial fibrosis. Only one specimen in group I had evidence for increased fibrosis and hypertrophy. Of the six subjects in group I who were evaluated for anthracycline changes, the mean (+ SD) score on the Billingham scale'2 was 1.42 + 0.49 (mild amount of damage, < 15% cells involved). Of the three subjects in groups II and III who received doxorubicin, two subjects in group II had respective biopsy scores of grade 1 and 2.5 and were thought to have "mixed etiology" cardiomyopathy with doxorubicin as a contributing factor, whereas the group III subject had a grade 3.0 biopsy score and was diagnosed as having uncomplicated anthracycline cardiomyopathy. Figure 5 shows the serum ionized calcium level in groups A and B at baseline and at the end of each of the 2 min calcium gluconate infusions. The slightly lower levels in group B were not statistically different from the levels reached in group A. Table 7 shows the mean hemodynamic values during the dobutamine and calcium infusions in the two groups of patients (at the paced heart rate), and figure 6 gives the net increases in peak positive left ventricular dP/dt from baseline during the two drug infusions at the paced heart rate. Dobutamine produced incremental increases in peak positive dP/dt, cardiac index, and stroke work index, which were accompanied by modest reductions in left ventricular end-diastolic pressure and a slight increase in mean arterial pressure (table 7) . The downward trend of /3-receptor density in the three groups as biventricular dysfunction increased indicated a significant relationship between decrease in f-receptor density and the degree of heart failure. The fact that ICYP dissociation constants were not different among the three groups supports the concept that myocardial fi-adrenergic receptors are not structurally altered by heart failure, and that the decrease in Bmax is secondary to a decrease in receptor density. This down-regulation of the human ventricular ,3-adrenergic receptor in heart failure is quantitatively similar to previously published findings in gram quantities of human heart, in which severely failing left ventricles were found to have reductions in receptor density of 50% to 53%," 21 similar to the reduction of 53% to 67% in severely failing right ventricles in the current study.
The ability to obtain cardiac tissue from ambulatory subjects by catheterization procedures allowed us to assess for the first time myocardial /-receptor density in subjects with mild to moderate heart failure. The data indicated that fl-receptor density is decreased in this group as compared with normals but that receptor density is higher than that encountered in the more severely failing group. The collective statistical analysis of these data was consistent with a stepwise reduction in cardiac fl-receptor density progressing from normal function to mild-to-moderate dysfunction to severe dysfunction. Therefore, f8-receptor down-regulation in the failing human heart appears to occur even in subjects with mild-to-moderate heart failure and is not strictly confined to subjects with severe failure.
The pharmacologic consequences of a reduction in fl-receptor density in the intact human heart were further examined in a subgroup of seven minimally to mildly failing and 11 severely failing hearts that were given dobutamine and calcium sequentially. In the severely failing subgroup, the LVEF and fl-receptor density were lower by 58% and 50%. However, all these measurements have been previous-1300 CIRCULATION ly performed in gram-quantity aliquots of explanted human heart, in which no apparent significant change in /8-agonist affinity occurs,25 adenylate cyclase responsiveness is blunted,"4 and /, -receptors down-regulate to a much greater extent than /32-receptors. 21 Based on the amount of tissue required to perform each of these determinations, in endomyocardial biopsy tissue only one of these assays or a receptor density measurement can be performed at any one time. Since any of the four can be performed in endomyocardial biopsy tissue by means of modifications of the methods outlined in this investigation, ultimately all these aspects of /3-adrenergic receptor regulation can be examined in the intact human heart.
Mechanisms responsible for /3-adrenergic receptor down-regulation in the failing human heart have not been addressed by this study. However, in an ongoing investigation (Bristow MR, unpublished data) testing the hypothesis that adrenergic stimulation accounts for /3-receptor down-regulation in diffuse cardiomyopathy (n = 15), cardiac venous norepinephrine level (mean + SEM, 609 ± 156 pg/ml) and coronary sinus norepinephrine level (740 ± 166 pg/ml) correlate inversely and significantly (r = .73 for central venous, .66 for coronary sinus, both p < .05) with /3-adrenergic receptor density in right ventricular biopsy specimens (31.0 ± 5.3 fmol/mg). Thus exposure to endogenous /3-agonists could account for myocardial /3-adrenergic down-regulation in the failing human heart.26 However, other explanations for heart failure-associated /3-adrenergic receptor down-regulation are also possible.
Observations made in this investigation provide additional evidence for the potential importance of myocardial /3-adrenergic receptor regulatory events in the natural history of heart failure. The decreased /3-receptor density would be expected to compromise the ability of endogenous catecholamines to support cardiac function,I14A7 and this effect may be manifest relatively early in the clinical course at a time when only mild to moderate heart failure is present.
Right ventricular endomyocardial biopsy is currently a readily available technique in many medical centers and has been shown to be as safe as other cardiac catheterization procedures.`0 The ability to measure /3-adrenergic receptors in intact human hearts can potentially increase our understanding of the myocardial cellular changes that occur in heart failure and of changes produced by drug therapy. With the techniques described in this study, hypotheses concerning /3-adrenergic receptor regulation in the human heart can be easily tested prospectively in intact human subjects.
